Literature DB >> 11668074

Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons.

J L Morris1, P Jobling, I L Gibbins.   

Abstract

The role of the soluble NSF attachment protein receptor (SNARE) protein complex in release of multiple cotransmitters from autonomic vasodilator neurons was examined in isolated segments of guinea pig uterine arteries treated with botulinum neurotoxin A (BoNTA; 50 nM). Western blotting of protein extracts from uterine arteries demonstrated partial cleavage of synaptosomal-associated protein of 25 kDa (SNAP-25) to a NH2-terminal fragment of approximately 24 kDa by BoNTA. BoNTA reduced the amplitude (by 70-80%) of isometric contractions of arteries in response to repeated electrical stimulation of sympathetic axons at 1 or 10 Hz. The amplitude of neurogenic relaxations mediated by neuronal nitric oxide (NO) was not affected by BoNTA, whereas the duration of peptide-mediated neurogenic relaxations to stimulation at 10 Hz was reduced (67% reduction in integrated responses). In contrast, presynaptic cholinergic inhibition of neurogenic relaxations was abolished by BoNTA. These results demonstrate that the SNARE complex has differential involvement in release of cotransmitters from the same autonomic neurons: NO release is not dependent on synaptic vesicle exocytosis, acetylcholine release from small vesicles is highly dependent on the SNARE complex, and neuropeptide release from large vesicles involves SNARE proteins that may interact differently with regulatory factors such as calcium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668074     DOI: 10.1152/ajpheart.2001.281.5.H2124

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  25 in total

1.  Differential involvement of N-type calcium channels in transmitter release from vasoconstrictor and vasodilator neurons.

Authors:  Judy L Morris; Daina I Ozols; Richard J Lewis; Ian L Gibbins; Phillip Jobling
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  Evidence-based knee injections for the management of arthritis.

Authors:  Olivia T Cheng; Dmitri Souzdalnitski; Bruce Vrooman; Jianguo Cheng
Journal:  Pain Med       Date:  2012-05-23       Impact factor: 3.750

Review 4.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 5.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

Review 6.  Botulinum toxin for the treatment of musculoskeletal pain and spasm.

Authors:  Geoffrey Sheean
Journal:  Curr Pain Headache Rep       Date:  2002-12

7.  Botulinum toxin type A suppresses arterial vasoconstriction by regulating calcium sensitization and the endothelium-dependent endothelial nitric oxide synthase/soluble guanylyl cyclase/cyclic guanosine monophosphate pathway: An in vitro study.

Authors:  Liang Hu; Ya Feng; Wuchao Liu; Lingjing Jin; Zhiyu Nie
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-23

Review 8.  Management of bladder, prostatic and pelvic floor disorders.

Authors:  G Brisinda; G Maria; A R Bentivoglio; F Cadeddu; G Marniga; F Brandara; A Albanese
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 9.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

10.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.